As a humanized monoclonal antibody, Nimotuzumab has a high affinity and can bind to the extracellular domain of EGFR and inhibit EGF binding [48] Nimotuzumab has been approved in several countries for the treatment of HNSCC [49] and glioma [50] based on clinical trials of various malignancies [51]. The gene discussed is EGF; the disease is head and neck squamous cell carcinoma.